TriSalus Life Sciences closed its business combination with MedTech Acquisition. TriSalus’ stock and warrants began trading today on the Nasdaq under the ticker symbols TLSI and TLSIW.
TriSalus is an oncology company integrating its delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors.
Redemptions ahead of the deal’s approval by MedTech shareholders Tuesday left about $2.6 million in the SPAC’s trust. Those funds supplement MedTech’s subscription agreement for nearly $18 million in convertible preferred stock.
The deal was announced in November at a $244.4 million post-close market cap. Read more.
